key: cord-0718853-jth59ut7
authors: Rybicki, Frank J
title: 3D Printing in Medicine: COVID-19 Testing with 3D Printed Nasopharyngeal Swabs
date: 2020-09-19
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1437
sha: ead7b253fad57798020fa24f6fa0574483bf9edc
doc_id: 718853
cord_uid: jth59ut7

nan

A c c e p t e d M a n u s c r i p t 3D printing a device to collect human COVID-19 samples was an unlikely intersection point for two cultures to collide. These cultures shed perspective on the article by Decker et al (1) and show how people with no prior information on infectious diseases impacted the pandemic response (2)usually for better, but sometimes for worse.

The first culture is generally called the "maker culture" and includes 3D printing; it embraces and thrives on the open exchange of ideas, repurposing and making incremental improvements on designs via websites, and publications among like-minded "makers". Neither profitability nor global impact is ignored, but they typically fall in line with the "maker" culture of collaboration and advancement of science. The second culture is embedded within medical device companies and other 3D printing companies with verticals in the medical sector. That culture follows more traditional profitability and scalability inherent in marketing and selling products that are cleared for intended use, for example by the US Food and Drug Administration (FDA) or Health Canada. Based on over a decade of experience and practical circumstances, that culture includes unpublished quality control methods, trade secrets, and customer (e.g. hospitals and individual physician) relationships.

In 2016, the Radiological Society of North America (RSNA) launched a Special Interest Group (SIG) on 3D Printing (3). One important, long term goal was to gently and patiently fold together these two cultures (4) . This included creating a new membership category within a nearly century-old society where industry members could, for the first time, join the RSNA with equal voting privileges to physicians. A figurative creative kitchen developed, with the first recipes focused on clinically appropriate 3D printed representations of CT scans and surgical guides (5) . COVID-19, a paucity of information about testing, and the resulting critical shortage of the nasopharyngeal swabs hasat least in the short termmoved that work from a kitchen to a cyclotron laboratory. At light speed, the collision of cultures and participants produced many impressive results, and it also revealed shortcomings. The purpose of this editorial is to place the contribution of the Decker et al (1) into context of the larger 3D manufacturing community for the readership of Clinical Infectious Diseases.

Although USF Health holds provisional patents (first granted March 20, 2020) on the concept and design of the 3D printed swab, they immediately and freely provided it to hospitals and clinics to address supply chain shortages. The rationale was that swabs could be produced using desktop printers already present in hospital 3D printing labs, or "from (3D printing) bench to bedside". Based on my own experience, the cost of all materials per swab using the methods described is roughly 25 cents (Figure) .

Also, in the spirit of collaboration, the authors opened their clinical trial nationally, moving the local human research committee ethics approval (IRB) to a national platform (Western Institutional Review Board, Inc.) so that any investigator could collaborate. Furthermore, A c c e p t e d M a n u s c r i p t while the dire need for swabs remained, USF placed a 1-year embargo on any revenues from the swab itself, further enabling the design to be utilized by as many hospitals as possible and slow the spread of the virus. This good will was not always used constructively, and in some instances the ensuing behavior was deplorable. Some companies and individuals with the specific 3D printing platform used cultural good will and openness for profit. There were 3D printed swabs soldeven to state governments, with fees dramatically beyond costs. This avarice was compounded by the fact that hospitals and large agencies needed to conserve healthcare dollars more than ever. Others made small modifications to get around the patented design, with an additional negative consequence of inconsistency among the swabs. We now know that many related designs are safe and suitable for clinical use, but that uncertainty cost precious time and trust among infectious disease specialists, hospital administrators, and frontline workers who were used to the consistency seen in the packaging and feel of commercial products.

Infectious disease experts, pathologists, nurses, and leaders from the 3D printing in medicine community voiced concerns about how a printed swab could be as safe or gentle to the nasopharyngeal track when compared to the flocked swab. Volunteer testing (including those from USF Health and Northwell Health) showed that there were no differences in discomfort or issues with breakages (6) . Anecdotal reports suggested that some patients tested with both swabs preferred the 3D printed one, and training with a focus on the test tube break point provides reassurance. Additional data (7, 8) should be interpreted with the current demonstration that the 3D printed swab is equivalent to commercial flocked swabs (1).

Chemical compounds are essential to 3D printing, particularly in medical applications when there is contact between the 3D printed part and the patient. In part because of the two different cultures, many medical experts are not familiar with how deeply 3D printing has permeated medicine and dentistry. Subsequently, there was and still is a misconception regarding the ability of an in-hospital 3D printed lab to generate a part that is equivalent to a commercial product for an intended use. The swabs are created from a surgical grade material cleared to come in contact with internal human tissues. The 3D printed swabs are rinsed in isopropyl alcohol (9) and cured following guidelines to ensure that they are not cytotoxic. 3D printing quality assurance includes an individual human review of each swab to ensure that it appears straight, is free from defects, and has no residual resinall before an infectious disease team re-examines each swab, autoclaves them, and then bundles them with the rest of the test kit materials. M a n u s c r i p t

From the FDA"s perspective, the key difference between the nasopharyngeal swab and other 3D printed parts (10) during the COVID-19 pandemic is the fact that swabs must be used sterile. Specifically, the risk of the swab contaminating the test result has elevated the overall efforts into a more controlled Class I ("one") exempt status for medical devices (11) . The FDA reviews and lists Class I medical devices, although they are not considered "cleared" as is commonly referred to for Class II medical devices. Nonetheless, cultural disconnect, regulatory illiteracy and some skepticism prompted hospital administrators to repeatedly ask that 3D printed swabs "be cleared by the FDA". The demand for clarity and discussion stirred up enough controversy that the FDA convened a special mid-pandemic Virtual Town Hall on May 15 th ; unofficial attendance count may have been 1000 attendees (12) . Over the past decade, and particularly during the past 5 years I have developed enormous respect for the role and responsibilities of the FDA to keep Americans safe, including admiration for the individuals who maintain this role for 3D printing and inherently are charged to help manage and integrate the different cultures.

Longer term data is lacking, and only a small number of sites are enrolled in any one study. USF Health provided coaching outside their institution during bench lab testing without requiring trial enrollment. Other hospitals had limited swabs, resorted to a "conservation" mode and were unwilling to use precious commercial swabs for any experimentation. Finally, the pediatric population is not represented by this study. Summary 3D printing has an expanding role in hospitals, enabling a novel pathway for medical engineers and scientists to work with physicians to positively impact patient care. COVID-19 supply shortages extended this role to infection disease specialists. While a 3D printing lab has the potential to generate a part that is equivalent to a commercial product cleared by the FDA for an intended use, cultural differences exist and impact the rate at which 3D printed parts will be made and used in hospitals. Among all parts 3D printed during COVID-19, nasopharyngeal swabs have received the most attention, with participants ranging from humanitarians to charlatans. The authors should be congratulated for staying on the right side of the curve, and for their perseverance, leadership, scientific rigor, and good will.

Dr. Rybicki has nothing to disclose.

3D Printed Alternative to the Standard Synthetic Flocked Nasopharyngeal Swabs Used for COVID-19 Testing

3D Printing in Medicine and Its Role in the COVID-19 Pandemic

RSNA) 3D printing Special Interest Group (SIG): guidelines for medical 3D printing and appropriateness for clinical scenarios

Medical 3D Printing for the Radiologist

Adverse effects of nasopharyngeal swabs: Threedimensional printed versus commercial swabs

United States National Institutes of Health and The Veterans Health Administration. VHA Nasal Swab Testing Protocols and Results

Open Development and Clinical Validation of Multiple 3D-Printed Sample-Collection Swabs: Rapid Resolution of a Critical COVID-19 Testing Bottleneck

A 3D-printed nasopharyngeal swab for COVID-19 diagnostic testing

COVID-19 and the role of 3D printing in medicine

United States Food and Drug Administration

Accessed 14

United States Food and Drug Administration

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t